Castrate-resistant Prostate Cancer Market To Reach $21.44 Billion By 2030

Castrate-resistant Prostate Cancer Market Growth & Trends

The global castrate-resistant prostate cancer market size is expected to reach  USD 21.44 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America’s dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

 Request a free sample copy or view report summary: Castrate-resistant Prostate Cancer Market Report

Castrate-resistant Prostate Cancer Market Report Highlights

• The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC.

• The immunotherapy segment is projected to grow at a CAGR of 11.9% from 2025 to 2030, driven by the increasing recognition of immunotherapy's potential to provide durable responses and improve overall survival in CRPC patients

• North America held the largest revenue share of 47.9% of the global castrate-resistant prostate cancer market in 2024

• Asia Pacific castrate-resistant prostate cancer market is anticipated to grow fastest throughout the forecast period, driven by the increasing prevalence of prostate cancer in densely populated countries such as China, Japan, and India

Castrate-resistant Prostate Cancer Market Segmentation

Grand View Research has segmented the global castrate-resistant prostate cancer market based on therapy and region:

Castrate-resistant Prostate Cancer Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Hormonal Therapy

• Immunotherapy

• Radiotherapy

Castrate-resistant Prostate Cancer Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Sweden

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Castrate-resistant Prostate Cancer Market 

• Sanofi

• Johnson & Johnson Services, Inc.

• Pfizer, Inc.

• Astellas Pharma, Inc.

• Bayer AG